ID: MRFR/Pharma/2808-HCR | February 2021 | Region: Global | 90 pages
Market Synopsis of Global Optic Nerve Glioma Market
Optic nerve glioma or optic glioma or juvenile pilocytic astrocytoma are types of brain tumour primarily affecting the optic nerve cells. Optic nerve gliomas are slow growing, rare and mostly found in children. Its occurrence in individuals over age 20 is quite rare and any occurrence is associated with the genetic disorder neurofibromatosis type 1, or NF1 in approximately 30% of the cases. Symptoms of an optic nerve glioma are nausea and vision disturbances, vomiting, balance problems, involuntary eye movements, memory impairment, delay in growth etc. ; daytime sleepiness is also witnessed in a large number of patients. The pressure exerted by these tumours may cause secondary effects such as hormonal problems due to effects on the pituitary gland. Optic nerve gliomas account for about 1% of all intracranial tumours. About 10% of optic nerve gliomas are located within an optic nerve, one third in both optic nerve and chiasm (left and right optic nerve crossing), and approximately one third involve the chiasm itself. The remaining one fourth optic nerve gliomas are in the hypothalamus and approximately 5 5% gliomas are multi-centric.
The treatment of optic nerve gliomas include surgery and radiation therapy. The drawbacks of surgery include high risk of brain damage and high costs. Surgery might not always be a good option due to location of the tumour. Radiation therapy for optic nerve gliomas has its own drawbacks such as damage to the eyes and brain, high costs and other side effects associated with its use such as vomiting, reduced immunity, hair loss etc. The primary aim of radiation therapy is to shrink the tumour and to kill any remaining cancer cells. Chemotherapy is used if the tumour has spread to other parts of the brain. Symptomatic and supportive treatment includes use of corticosteroids to reduce swelling etc. Most optic nerve gliomas are benign and malignant gliomas (glioblastoma) are rare and fatal.
The global optic nerve glioma market is expected to reach US$ 350 million by 2023, and the market is projected to grow at a CAGR of ~ 3.2 % during the forecast period 2017-2023.
Sources: Mayo Clinic, MRFR Analysis
Figure 1 Global Optic Nerve Glioma Market by Treatment, 2016 (% market share)
The global optic nerve glioma market has been segmented on the basis of types, diagnosis, treatment and end users.
Based on types, the market has been segmented as malignant optic nerve glioma and benign optic nerve glioma.
Based on the diagnosis, the market has been segmented into neurological exam, Computed Tomography (CT), Magnetic Resonance Imaging (MRI), biopsy and others.
Based on the treatment, the market has been segmented into surgery, radiation therapy, chemotherapy and others.
Based on the end users, the market has been segmented as pharmace hospitals and clinics, diagnostic centers and others.
The Americas account for a significant market share owing to extensive use of medications and high expenditure on the health care. Additionally, the fastest uptake of new technology in the US drives the global optic nerve glioma market. Also, concentration of major research companies and cancer research sector in the developed countries of this region is adding fuel to the market.
Europe is the second largest market in the world due to high income and healthcare penetration.
Asia Pacific region is expected to grow rapidly and China and India are likely to lead this market due to fast growing industrial sector during the forecast period.
Gulf nations such as Saudi Arabia and the UAE are estimated to drive the Middle East & African market. The African region is expected to witness a moderate growth owing to poor economic and political conditions and poor healthcare development.
Key Players in the Global Optic Nerve Glioma Market
Some of key players profiled in the report are Emcure Pharmaceuticals ltd., Sigma-Aldrich Co., Thermo Fisher Scientific Inc., Pfizer Inc., Taj Pharmaceuticals Limited, Novartis International AG, Teva Pharmaceutical Industries Ltd, GE Healthcare, Siemens Healthcare, Philips Healthcare, Shimadzu Corporation, Toshiba Medical Systems Corporation and others.
The report for Global Optic nerve glioma market by Market Research Future comprises of extensive primary research along with the detailed analysis of qualitative as well as quantitative aspects by various industry experts, key opinion leaders to gain a deeper insight of the market and industry performance. The report gives a clear picture of the current market scenario which includes past and estimated future market size with respect to value and volume, technological advancement, macro economical and governing factors in the market. The report provides detail information about and strategies used by top key players in the industry. The report also gives a broad study of the different market segments and regions.
Table of contents
1.2 Scope of Study
1.2.1 Research Objective
1.2.2 Assumptions & Limitations
1.3 Market Structure
2. Research Methodology
2.1 Research Process
2.2 Primary Research
2.3 Secondary Research
3. Market dynamics
3.4 Macroeconomic Indicators
4. Market factor analysis
4.1 Porters Five Forces Model
4.2 Bargaining Power of Suppliers
4.3 Bargaining Power of Buyers
4.4 Threat of New Entrants
4.5 Threat of Substitutes
4.6 Intensity of Rivalry
5. Global Optic Nerve Glioma Market, by Types
5.1 Malignant Optic Nerve Glioma
5.2 Benign Optic Nerve Glioma
6. Global Optic Nerve Glioma Market, by Diagnosis
6.2 Neurological Exam
6.3 Computed Tomography (CT)
6.4 Magnetic Resonance Imaging (MRI)
7. Global Optic Nerve Glioma Market, by Treatment
7.3 Radiation Therapy
8. Global Optic Nerve Glioma Market, by End Users
8.2 Hospitals & Clinics
8.3 Diagnostic Centers
9. Global Optic Nerve Glioma Market, by Region
9.1 North America
9.3 Asia Pacific
9.4 Middle East & Africa
10. Competitive landscape
10.1 Major Strategies Adopted by Market Players
10.1.1 Strategic Partnership
10.1.2 Merger & Acquisition
11. Company profile
11.1.2 Product Overview
11.1.4 Key Developments
11.2 Bio-Rad Laboratories, Inc.
11.2.2 Product Overview
11.2.4 Key Developments
11.3 Miltenyi Biotec
11.3.2 Product Overview
11.3.4 Key Development
11.4 BioLegend, Inc.
11.4.2 Product Overview
11.4.4 Key Developments
11.5 Becton, Dickinson and Company
11.5.2 Product Overview
11.5.4 Key Developments
11.6 Beckman Coulter, Inc.
11.6.2 Product Overview
11.6.4 Key Developments
11.7 Merck KGaA
11.7.2 Product Overview
11.7.4 Key Developments
11.8 ImmunoReagents, Inc.
11.8.2 Product Overview
11.8.4 Key Developments
11.9 Thermo Fisher Scientific
11.9.2 Product Overview
11.9.4 Key Developments
12.1 Key Findings
12.1.1 From CEO’s Viewpoint
12.1.2 Unmet Needs of The Market
12.2 Key Companies to Watch
12.3 Prediction of Optic Nerve Glioma Industry